The relationship between neurotrophins and bipolar disorder

References

• Merikangas KR, Akiskal HS, Angst J et al. Lifetime and 12-month prevalence ofbipolar spectrum disorder in the national comorbidity survey replication. Arch. Gen. Psychiatry 64(5), 543–552 (2007).
   PubMed Web of Science ®Google Scholar
• Merikangas KR, Jin R, He JP et al. Prevalence and Correlates of Bipolar Spectrum Disorder in the World Mental Health Survey Initiative. Arch. Gen. Psychiatry 68(3), 241–251 (2011).
   PubMed Web of Science ®Google Scholar
• Wyatt RJ, Henter I. An economic evaluation of manic-depressive illness--1991. Soc. Psychiatry Psychiatr. Epidemiol. 30(5), 213–219 (1995).
   PubMed Web of Science ®Google Scholar
• Gao K, Kemp DE, Wu R et al. Mood Stabilizers. In: Psychiatry (4th Edition). Tasman A, Liberman J, Kay J, First M, Riba M ( Eds). John Wiley and Sons, Ltd., West Sussex, UK (In Press).
   Google Scholar
• Gao K, Wu R, Grunze H et al. Phamarcological treatment of acute bipolar depression. In: Bipolar Disorder: Mellinium Upate.Yildiz A, Nemeroff C, Ruiz P ( Eds), Oxford University Press, New York, USA (In Press).
   Google Scholar
• Gao K, Kemp DE, Calabrese JR. Pharmacological treatment of the maintenance phase of bipolar depression: focus on relapse prevention studies and the impact of design on generalizability. In: Milestones in Drug Therapy, Bipolar Depression: Molecular Neurobiology, Clinical Diagnosis and Pharmacotherapy. Zarate CA, Manji HK ( Ed.), Spinger, Birkhauser Vertag, Switzerland, 159–178 (2009).
   Google Scholar
• Longo FM, Xie Y, Massa SM. Neurophin small molecule mimetics: candidate therapeutic agents for neurological disorders. Curr. Med. Chem. - Central Nervous System Agents 5, 26–41 (2005).
   Google Scholar
• Duman RS. Novel therapeutic approaches beyond the serotonin receptor. Biol. Psychiatry 44(5), 324–35 (1998).
   PubMedGoogle Scholar
• Craddock N, Jones I. Genetics of bipolar disorder. J. Med. Genet. 36(8), 585–594 (1999).
   PubMedGoogle Scholar
• Craddock N, Lendon C, Cichon S et al. Chromosome Workshop: Chromosomes 11, 14, and 15. Am. J. Med. Genet. 88(3), 244–254 (1999).
   PubMedGoogle Scholar
• Cargill M, Altshuler D, Ireland J et al. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat. Genet. 22(3), 231–238 (1999).
   PubMed Web of Science ®Google Scholar
• Sklar P, Gabriel SB, McInnis MG et al. Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus. Brain-derived neutrophic factor. Mol. Psychiatry 7(6), 579–593 (2002).
   PubMed Web of Science ®Google Scholar
• Neves-Pereira M, Mundo E, Muglia P et al. The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: Evidence from a family-based association study. Am. J. Hum. Genet. 71(3), 651–655 (2002).
   PubMed Web of Science ®Google Scholar
• Geller B, Badner JA, Tillman R et al. Linkage disequilibrium of the brain-derived neurotrophic factor Val66Met polymorphism in children with a prepubertal and early adolescent bipolar disorder phenotype. Am. J. Psychiatry 161(9), 1698–1700 (2004).
   PubMed Web of Science ®Google Scholar
• Kremeyer B, Herzberg I, Garcia J et al. Transmission distortion of BDNF variants to bipolar disorder type I patients from a South American population isolate. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141B(5), 435–439 (2006).
   PubMedGoogle Scholar
• Lohoff FW, Sander T, Ferraro TN et al. Confirmation of association between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) gene and bipolar I disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 139B(1), 51–53 (2005).
   PubMed Web of Science ®Google Scholar
• Muller DJ, De Luca V, Sicard T et al. Brain-derived neurotrophic factor (BDNF) gene and rapid-cycling bipolar disorder - Family-based association study. Br. J. Psychiatry 189, 317–323 (2006).
   PubMed Web of Science ®Google Scholar
• Liu LX, Foroud T, Xuei XL et al. Evidence of association between brain-derived neurotrophic factor gene and bipolar disorder. Psychiatr. Genet. 18(6), 267–274 (2008).
   PubMedGoogle Scholar
• Wang Z, Li Z, Chen J et al. Association of BDNF gene polymorphism with bipolar disorders in Han Chinese Population. Genes Brain Behav. 11(5), 524–528 (2012).
   PubMedGoogle Scholar
• Ivanova MA, Christova TN, Asan TS et al. Evidence of an association between bipolar disorder and rs16917237 in the BDNF gene in a Bulgarian sample. Psychiatr. Genet. 23(3), 141–142 (2013).
   PubMed Web of Science ®Google Scholar
• Xu J, Liu Y, Wang P et al. Positive association between the brain-derived neurotrophic factor (BDNF) gene and bipolar disorder in the Han Chinese Population. Am. J. Med. Genet. B Neuropsychiatr. Genet. 153B(1), 275–279 (2010).
   PubMedGoogle Scholar
• Nakata K, Ujike H, Sakai A et al. Association study of the brain-derived neurotrophic factor (BDNF) gene with bipolar disorder. Neurosci. Lett. 337(1), 17–20 (2003).
   PubMedGoogle Scholar
• Hong CJ, Huo SJ, Yen FC et al. Association study of a brain-derived neurotrophic-factor genetic polymorphism and mood disorders, age of onset and suicidal behavior. Neuropsychobiology 48(4), 186–189 (2003).
   PubMed Web of Science ®Google Scholar
• Neves-Pereira M, Cheung J, Pasdar A et al. BDNF gene is a risk factor for schizophrenia in a Scottish population. Mol. Psychiatry 10(2), 208–212 (2005).
   PubMed Web of Science ®Google Scholar
• Oswald P, Del-Favero J, Massat I et al. Non-replication of the brain-derived neurotrophic factor (BDNF) association in bipolar affective disorder: A Belgian patient-control study. Am. J. Med. Genet. B Neuropsychiatr. Genet. 129B(1), 34–35 (2004).
   PubMedGoogle Scholar
• Skibinska M, Hauser J, Czerski PM et al. Association analysis of brain-derived neurotrophic factor (BDNF) gene Val66Met polymorphism in schizophrenia and bipolar affective disorder. World J. Biol. Psychiatry 5(4), 215–220 (2004).
   PubMed Web of Science ®Google Scholar
• Craddock N, Forty L. Genetics of affective (mood) disorders. Eur. J. Hum. Genet. 14(6), 660–668 (2006).
   PubMed Web of Science ®Google Scholar
• Green EK, Raybould R, MacGregor S et al. Genetic variation of brain-derived neurotrophic factor (BDNF) in bipolar disorder - Case-control study of over 3000 individuals from the UK. Br. J. Psychiatry 188, 21–25 (2006).
   PubMed Web of Science ®Google Scholar
• Ye CY, Xu YQ, Hu H et al. [An association study of brain-derived neurotrophic factor gene polymorphism in bipolar disorders]. Zhonghua yi xue za zhi 89(27), 1897–1901 (2009).
   PubMedGoogle Scholar
• Fan J, Sklar P. Genetics of bipolar disorder: focus on BDNF Val66Met polymorphism. Novartis Foundation symposium 289, 60–72 (2008).
   PubMedGoogle Scholar
• Min HJ, Cho HS, Kim SJ et al. Association of the brain-derived neurotrophic factor gene and clinical features of bipolar disorder in Korea. Clin. Psychopharmacol. Neurosci.10(3), 163–167 (2012).
   PubMedGoogle Scholar
• Rybakowski JK, Borkowska A, Czerski PM et al. Polymorphism of the brain-derived neurotrophic factor gene and performance on a cognitive prefrontal test in bipolar patients. Bipolar Disord. 5(6), 468–472 (2003).
   PubMedGoogle Scholar
• Tang J, Xiao L, Shu C et al. Association of the brain-derived neurotrophic factor gene and bipolar disorder with early age of onset in mainland China. Neurosci.Lett. 433(2), 98–102 (2008).
   PubMedGoogle Scholar
• Strauss J, Barr CL, George CJ et al. Association study of brain-derived neurotrophic factor in adults with a history of childhood onset mood disorder. Am. J. Med. Gene.t B Neuropsychiatr. Genet. 131B(1), 16–19 (2004).
   PubMedGoogle Scholar
• Adams JH, Wigg KG, King N et al. Association study of neurotrophic tyrosine kinase receptor type 2 (NTRK2) and childhood-onset mood disorders. Am. J. Med. Genet. B Neuropsychiat.r Genet. 132B(1), 90–95 (2005).
   PubMedGoogle Scholar
• Rybakowski JK, Borkowska A, Skibinska M et al. Illness-specific association of val66met BDNF polymorphism with performance on Wisconsin Card Sorting Test in bipolar mood disorder. Mol. Psychiatry 11(2), 122–124 (2006).
   PubMedGoogle Scholar
• Moreira L, Neves FS, Romano-Silva MA et al. BDNF and episodic memory in patients with bipolar disorder. Rev. Bras. Psiquiatr. 33(1), 96–97 (2011).
   PubMedGoogle Scholar
• Gruber O, Hasan A, Scherk H et al. Association of the brain-derived neurotrophic factor val66met polymorphism with magnetic resonance spectroscopic markers in the human hippocampus: in vivo evidence for effects on the glutamate system. Eur. Arch. Psychiatry Clin. Neurosci. 262(1), 23–31 (2012).
   Google Scholar
• Tramontina JF, Yates D, Magalhaes PVD et al. Brain-derived neurotrophic factor gene val66met polymorphism and executive functioning in patients with bipolar disorder. Rev. Bras. Psiquiatr. 31(2), 136–140 (2009).
   PubMedGoogle Scholar
• Zeni CP, Tramontina S, Zeni TA et al. The Val66Met polymorphism at the BDNF gene does not influence Wisconsin Card Sorting Test results in children and adolescents with bipolar disorder. Rev. Bras. Psiquiatr. 35(1), 44–50 (2013).
   PubMed Web of Science ®Google Scholar
• Joseph MF, Frazier TW, Youngstrom EA et al. A quantitative and qualitative review of neurocognitive performance in pediatric bipolar disorder. J. Child Adolesc. Psychopharmacol. 18(6), 595–605 (2008).
   PubMed Web of Science ®Google Scholar
• Vöhringer PA, Barroilhet SA, Amerio A et al. Cognitive impairment in bipolar disorder and schizophrenia: a systematic review. Front. Psychiatry 4, 87 (2013).
   PubMedGoogle Scholar
• Gao K, Wang Z, Chen J et al. Should an assessment of Axis I comorbidity be included in the initial diagnostic assessment of mood disorders? Role of QIDS-16-SR total score in predicting number of Axis I comorbidity. J. Affect. Disord. 148(2–3), 256–264 (2013).
   PubMed Web of Science ®Google Scholar
• Neves FS, Malloy-Diniz L, Romano-Silva MA et al. The role of BDNF genetic polymorphisms in bipolar disorder with psychiatric comorbidities. J. Affect. Disord. 131(1–3), 307–311 (2011).
   PubMedGoogle Scholar
• Koppel I, Aid-Pavlidis T, Jaanson K et al. Tissue-specific and neural activity-regulated expression of human BDNF gene in BAC transgenic mice. BMC Neurosci. 10, 68 (2009).
   PubMed Web of Science ®Google Scholar
• Pandey GN, Dwivedi Y. Brain-derived neurotrophic factor gene and protein expression in pediatric and adult depressed subjects. Prog. Neuropsychopharmacol Biol. Psychiatry 34(6), 1161–1161 (2010).
   Google Scholar
• Pandey GN, Rizavi HS, Dwivedi Y et al. Brain-derived neurotrophic factor gene expression in pediatric bipolar disorder: effects of treatment and clinical response. J. Am. Acad. Child Adolesc. Psychiatry 47(9), 1077–1085 (2008).
   PubMedGoogle Scholar
• D’Addario C, Dell’Osso B, Palazzo MC et al. Selective DNA Methylation of BDNF promoter in bipolar disorder: differences among patients with BDI and BDII. Neuropsychopharmacology 37(7), 1647–1655 (2012).
   PubMed Web of Science ®Google Scholar
• Dunham JS, Deakin JFW, Miyajima F et al. Expression of hippocampal brain-derived neurotrophic factor and its receptors in Stanley consortium brains. J. Psychiatr. Res. 43(14), 1175–1184 (2009).
   PubMed Web of Science ®Google Scholar
• Pillai A. Decreased expression of sprouty2 in the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder: A positive correlation with BDNF expression. Biol. Psychiatry 63(7), 107s (2008).
   Google Scholar
• Thompson Ray M, Weickert CS, Wyatt E et al. Decreased BDNF, trkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders. J. Psychiatry Neurosci. 36(3), 195–203 (2011).
   PubMed Web of Science ®Google Scholar
• Soontornniyomkij B, Everall IP, Chana G et al. Tyrosine kinase B protein expression is reduced in the cerebellum of patients with bipolar disorder. J. Affect. Disord. 133(3), 646–654 (2011).
   PubMedGoogle Scholar
• De Luca V, Strauss J, Semeralul M et al. Analysis of BDNF Val66Met allele-specific mRNA levels in bipolar disorder. Neurosci. Lett. 441(2), 229–232 (2008).
   PubMedGoogle Scholar
• Munkholm K, Vinberg M, Berk M et al. State-related alterations of gene expression in bipolar disorder: a systematic review. Bipolar Disord. 14(7), 684–696 (2012).
   PubMed Web of Science ®Google Scholar
• Chepenik LG, Fredericks C, Papademetris X et al. Effects of the brain-derived neurotrophic growth factor Val66Met variation on hippocampus morphology in bipolar disorder. Neuropsychopharmacology 34(4), 944–951 (2009).
   PubMedGoogle Scholar
• Matsuo K, Walss-Bass C, Nery FG et al. Neuronal correlates of brain-derived neurotrophic factor Val66Met polymorphism and morphometric abnormalities in bipolar disorder. Neuropsychopharmacology 34(8), 1904–1913 (2009).
   PubMedGoogle Scholar
• Frodl T, Schuele C, Schmitt G et al. Association of the brain-derived neurotrophic factor Val66Met polymorphism with reduced hippocampal volumes in major depression. Arch. Gen. Psychiatry 64(4), 410–416 (2007).
   PubMed Web of Science ®Google Scholar
• Montag C, Weber B, Fliessbach K et al. The BDNF Val66Met polymorphism impacts parahippocampal and amygdala volume in healthy humans: incremental support for a genetic risk factor for depression. Psychol. Med. 39(11), 1831–1839 (2009).
   PubMedGoogle Scholar
• Teh CA, Lee TS, Kuchibhatla M et al. Bipolar disorder, brain-derived neurotrophic factor (BDNF) Val66Met polymorphism and brain morphology. PloS ONE 7(7), e38469 (2012).
   PubMed Web of Science ®Google Scholar
• Selvaraj S, Arnone D, Job D et al. Grey matter differences in bipolar disorder: a meta-analysis of voxel-based morphometry studies. Bipolar Disord. 14(2), 135–145 (2012).
   PubMed Web of Science ®Google Scholar
• Hafeman DM, Chang KD, Garrett AS et al. Effects of medication on neuroimaging findings in bipolar disorder: an updated review. Bipolar Disord. 14(4), 375–410 (2012).
   PubMed Web of Science ®Google Scholar
• Mirakhur A, Moorhead TW, Stanfield AC et al. Changes in gyrification over 4 years in bipolar disorder and their association with the brain-derived neurotrophic factor valine(66) methionine variant. Biol. Psychiatry 66(3), 293–297 (2009).
   PubMed Web of Science ®Google Scholar
• McIntosh AM, Moorhead TW, McKirdy J et al. Temporal grey matter reductions in bipolar disorder are associated with the BDNF Val66Met polymorphism. Mol. Psychiatry 12(10), 902–903 (2007).
   PubMedGoogle Scholar
• Frey BN, Walss-Bass C, Stanley JA et al. Brain-derived neurotrophic factor val66met polymorphism affects prefrontal energy metabolism in bipolar disorder. Neuroreport 18(15), 1567–1570 (2007).
   PubMedGoogle Scholar
• Gallinat J, Schubert F, Bruhl R et al. Met carriers of BDNF Val66Met genotype show increased N-acetylaspartate concentration in the anterior cingulate cortex. Neuroimage 49(1), 767–771 (2010).
   PubMedGoogle Scholar
• Tsai SJ. Is mania caused by overactivity of central brain-derived neurotrophic factor? Med. Hypotheses 62(1), 19–22 (2004).
   PubMedGoogle Scholar
• Machado-Vieira R, Dietrich MO, Leke R et al. Decreased plasma brain derived neurotrophic factor levels in unmedicated bipolar patients during manic episode. Biol. Psychiatry 61(2), 142–144 (2007).
   PubMedGoogle Scholar
• de Oliveira GS, Cereser KM, Fernandes BS et al. Decreased brain-derived neurotrophic factor in medicated and drug-free bipolar patients. J. Psychiatr. Res. 43(14), 1171–1174 (2009).
   PubMed Web of Science ®Google Scholar
• Cunha AB, Frey BN, Andreazza AC et al. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci. Lett. 398(3), 215–219 (2006).
   PubMed Web of Science ®Google Scholar
• Fernandes BS, Gama CS, Kauer-Sant’Anna M et al. Serum brain-derived neurotrophic factor in bipolar and unipolar depression: a potential adjunctive tool for differential diagnosis. J. Psychiatr. Res. 43(15), 1200–1204 (2009).
   PubMedGoogle Scholar
• Chou YH, Wang SJ, Lirng JF et al. Impaired cognition in bipolar I disorder: the roles of the serotonin transporter and brain-derived neurotrophic factor. J. Affect. Disord. 143(1–3), 131–137 (2012).
   PubMedGoogle Scholar
• Dias VV, Brissos S, Frey BN et al. Cognitive function and serum levels of brain-derived neurotrophic factor in patients with bipolar disorder. Bipolar Disord. 11(6), 663–671 (2009).
   PubMed Web of Science ®Google Scholar
• Huang TL, Hung YY, Lee CT et al. Serum protein levels of brain-derived neurotrophic factor and tropomyosin-related kinase B in bipolar disorder: effects of mood stabilizers. Neuropsychobiology 65(2), 65–69 (2012).
   PubMedGoogle Scholar
• Monteleone P, Serritella C, Martiadis V et al. Decreased levels of serum brain-derived neurotrophic factor in both depressed and euthymic patients with unipolar depression and in euthymic patients with bipolar I and II disorders. Bipolar Disord. 10(1), 95–100 (2008).
   PubMedGoogle Scholar
• Hashimoto K. Brain-derived neurotrophic factor as a biomarker for mood disorders: An historical overview and future directions. Psychiatry Clin. Neurosci. 64(4), 341–357 (2010).
   PubMed Web of Science ®Google Scholar
• Barbosa IG, Huguet RB, Mendonca VA et al. Increased plasma levels of brain-derived neurotrophic factor in patients with long-term bipolar disorder. Neurosci. Lett. 475(2), 95–98 (2010).
   PubMed Web of Science ®Google Scholar
• Barbosa IG, Rocha NP, Huguet RB et al. Executive dysfunction in euthymic bipolar disorder patients and its association with plasma biomarkers. J. Affect. Disord. 137(1–3), 151–155 (2012).
   PubMed Web of Science ®Google Scholar
• Barbosa IG, Rocha NP, de Miranda AS et al. Increased BDNF levels in long-term bipolar disorder patients. Rev. Bras. Psiquiatr. 35(1), 67–69 (2013).
   PubMed Web of Science ®Google Scholar
• Lin PY. State-dependent decrease in levels of brain-derived neurotrophic factor in bipolar disorder: a meta-analytic study. Neurosci. Lett. 466(3), 139–143 (2009).
   PubMed Web of Science ®Google Scholar
• Fernandes BS, Gama CS, Cereser KM et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J. Psychiatr. Res. 45(8), 995–1004 (2011).
   PubMed Web of Science ®Google Scholar
• Rybakowski JK, Suwalska A. Excellent lithium responders have normal cognitive functions and plasma BDNF levels. Int. J. Neuropsychophamcol. 13(5), 617–622 (2010).
   PubMedGoogle Scholar
• Suwalska A, Sobieska M, Rybakowski JK. Serum brain-derived neurotrophic factor in euthymic bipolar patients on prophylactic lithium therapy. Neuropsychobiology 62(4), 229–234 (2010).
   PubMed Web of Science ®Google Scholar
• Tramontina JF, Andreazza AC, Kauer-Sant’Anna M et al. Brain-derived neurotrophic factor serum levels before and after treatment for acute mania. Neurosci. Lett. 452(2), 111–113 (2009).
   PubMed Web of Science ®Google Scholar
• de Sousa RT, van de Bilt MT, Diniz BS et al. Lithium increases plasma brain-derived neurotrophic factor in acute bipolar mania: a preliminary 4-week study. Neurosci. Lett. 494(1), 54–56 (2011).
   PubMed Web of Science ®Google Scholar
• Tseng M, Alda M, Xu L et al. BDNF protein levels are decreased in transformed lymphoblasts from lithium-responsive patients with bipolar disorder. J. Psychiatry Neurosci. 33(5), 449–453 (2008).
   PubMedGoogle Scholar
• Yoshimura R,Nakano Y, Hori H et al. Effect of risperidone on plasma catecholamine metabolites and brain-derived neurotrophic factor in patients with bipolar disorders. Hum. Psychopharmacol. 21(7), 433–438 (2006).
   Google Scholar
• Grande I, Kapczinski F, Stertz L et al. Peripheral brain-derived neurotrophic factor changes along treatment with extended release quetiapine during acute mood episodes: An open-label trial in drug-free patients with bipolar disorder. J. Psychiatr. Res. 46(11), 1511–1514 (2012).
   PubMed Web of Science ®Google Scholar
• Yoshimura R, Ikenouchi-Sugita A, Hori H et al. Adding a low dose atypical antipsychotic drug to an antidepressant induced a rapid increase of plasma brain-derived neurotrophic factor levels in patients with treatment-resistant depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 34(2), 308–312 (2010).
   PubMedGoogle Scholar
• Fernandes B, Gama CS, Massuda R et al. Serum brain-derived neurotrophic factor (BDNF) is not associated with response to electroconvulsive therapy (ECT): a pilot study in drug resistant depressed patients. Neurosci. Lett. 453(3), 195–198 (2009).
   PubMed Web of Science ®Google Scholar
• D’Sa C, Dileone RJ, Anderson GM et al. Serum and plasma brain-derived neurotrophic factor (BDNF) in abstinent alcoholics and social drinkers. Alcohol 46(3), 253–259 (2012).
   PubMed Web of Science ®Google Scholar
• Vinberg M, Trajkovska V, Bennike B et al. The BDNF Val66Met polymorphism: relation to familiar risk of affective disorder, BDNF levels and salivary cortisol. Bipolar Disord. 11, 12–13 (2009).
   Google Scholar
• Hosang GM, Uher R, Keers R et al. Stressful life events and the brain-derived neurotrophic factor gene in bipolar disorder. J. Affect. Disord. 125(1–3), 345–349 (2010).
   PubMedGoogle Scholar
• Schule C, Zill P, Baghai TC et al. Brain-derived neurotrophic factor Val66Met polymorphism and dexamethasone/CRH test results in depressed patients. Psychoneuroendocrinology 31(8), 1019–1025 (2006).
   PubMedGoogle Scholar
• Miller S, Hallmayer J, Wang PW et al. Brain-derived neurotrophic factor val66met genotype and early life stress effects upon bipolar course. J. Psychiatr. Res. 47(2), 252–258 (2013).
   PubMed Web of Science ®Google Scholar
• Chen J, Fang Y, Kemp DE et al. Switching to Hypomania and Mania: Differential Neurochemical, Neuropsychological, and Pharmacologic Triggers and Their Mechanisms. Curr. Psychiatry Rep. 12(6), 512–521 (2010).
   PubMedGoogle Scholar
• Wu R, Gao K, Calabrese JR et al. Treatment Induced Mood Instability: Treatment – Emergent Affective Switches and Cycle Acceleration. In: Bipolar Disorder: Millennium Update. Yildiz A, Nemeroff C, Ruiz P ( Eds), Oxford University Press, New York, USA, in press
   Google Scholar
• Vincze I, Perroud N, Buresi C et al. Association between brain-derived neurotrophic factor gene and a severe form of bipolar disorder, but no interaction with the serotonin transporter gene. Bipolar Disord.10(5), 580–587 (2008).
   PubMedGoogle Scholar
• Lee S-Y, Chen S-L, Wang Y-S et al. COMT and BDNF interacted in bipolar II disorder not comorbid with anxiety disorder. Behav. Brain Res. 237(0), 243–248 (2013).
   PubMedGoogle Scholar
• Huang CC, Chang YH, Lee SY et al. The interaction between BDNF and DRD2 in bipolar II disorder but not in bipolar I disorder. Am. J Med. Genet. B Neuropsychiatr. Genet. 2159B(5), 501–507 (2012).
   Google Scholar
• Lee SY, Lu RB. Interaction of the DRD3 and BDNF gene variants in subtype bipolar disorder. Bipolar Disord. 14, 96–96 (2012).
   Google Scholar
• Goldstein BI, Kemp DE, Soczynska JK et al. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J. Clin. Psychiatry 70(8), 1078–1090 (2009).
   PubMed Web of Science ®Google Scholar
• Su SC, Sun MT, Wen MJ et al. Brain-derived neurotrophic factor, adiponectin, and proinflammatory markers in various subtypes of depression in young men. Int. J. Psychiatry Med. 42(3), 211–226 (2011).
   PubMed Web of Science ®Google Scholar
• Goldstein BI, Collinger KA, Lotrich F et al. Preliminary findings regarding proinflammatory markers and brain-derived neurotrophic factor among adolescents with bipolar spectrum disorders. J. Child Adolesc. Psychopharmacol. 21(5), 479–484 (2011).
   PubMed Web of Science ®Google Scholar
• Kauer-Sant’Anna M, Kapczinski F, Andreazza AC et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int. J. Neuropsychopharmacol. 12(4), 447–458 (2009).
   PubMed Web of Science ®Google Scholar
• Rybakowski JK, Suwalska A, Skibinska M et al. Prophylactic lithium response and polymorphism of the brain-derived neurotrophic factor gene. Pharmacopsychiatry 38(4), 166–170 (2005).
   PubMedGoogle Scholar
• Dmitrzak-Weglarz M, Rybakowski JK, Suwalska A et al. Association studies of the BDNF and the NTRK2 gene polymorphisms with prophylactic lithium response in bipolar patients. Pharmacogenomics 9(11), 1595–1603 (2008).
   PubMedGoogle Scholar
• Masui T, Hashimoto R, Kusumi I et al. Lithium response and Val66Met polymorphism of the brain-derived neurotrophic factor gene in Japanese patients with bipolar disorder. Psychiatr. Genet. 16(2), 49–50 (2006).
   PubMedGoogle Scholar
• Michelon L, Meira-Lima I, Cordeiro Q et al. Association study of the INPP1, 5HTT, BDNF, AP-2beta and GSK-3beta GENE variants and restrospectively scored response to lithium prophylaxis in bipolar disorder. Neurosci. Lett. 403(3), 288–293 (2006).
   PubMedGoogle Scholar
• Rybakowski JK, Suwalska A, Skibinska M et al. Response to lithium prophylaxis: Interaction between serotonin transporter and BDNF genes. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B(6), 820–823 (2007).
   PubMedGoogle Scholar
• Severino G, Squassina A, Costa M et al. Pharmacogenomics of bipolar disorder. Pharmacogenomics 14(6), 655–674 (2013).
   PubMed Web of Science ®Google Scholar
• Chiu C-T, Chuang D-M. Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Pharmacol. Ther. 128(2), 281–304 (2010)
   PubMed Web of Science ®Google Scholar
• Machado-Vieira R, Manji HK, Zarate CA. The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord. 11, 92–109 (2009).
   PubMed Web of Science ®Google Scholar
• Gupta A, Schulze TG, Nagarajan V et al. Interaction networks of lithium and valproate molecular targets reveal a striking enrichment of apoptosis functional clusters and neurotrophin signaling. Pharmacogenomics J. 12(4), 328–341 (2012).
   PubMedGoogle Scholar
• Malhi GS, Tanious M, Das P et al. Potential mechanisms of action of lithium in bipolar disorder current understanding. CNS Drugs 27(2), 135–153 (2013).
   PubMed Web of Science ®Google Scholar
• McQuillin A, Rizig M, Gurling HM. A microarray gene expression study of the molecular pharmacology of lithium carbonate on mouse brain mRNA to understand the neurobiology of mood stabilization and treatment of bipolar affective disorder. Pharmacogenet. Genomics17(8), 605–617 (2007).
   PubMed Web of Science ®Google Scholar
• Li N, He X, Qi X et al. The mood stabilizer lamotrigine produces antidepressant behavioral effects in rats: role of brain-derived neurotrophic factor. J. Psychopharmacol. 24(12), 1772–1778 (2010).
   PubMedGoogle Scholar
• Li N, He X, Zhang Y et al. Brain-derived neurotrophic factor signalling mediates antidepressant effects of lamotrigine. Int. J. Neuropsychopharmacol. 14(8), 1091–1098 (2011).
   PubMed Web of Science ®Google Scholar
• Hammonds MD, Shim SS. Effects of 4-week treatment with lithium and olanzapine on levels of brain-derived neurotrophic factor, B-cell CLL/lymphoma 2 and phosphorylated cyclic adenosine monophosphate response element-binding protein in the sub-regions of the hippocampus. Basic Clin. Pharmacol. Toxicol. 105(2), 113–119 (2009).
   PubMedGoogle Scholar
• Zai G, Mundo E, Strauss J et al. Brain-derived neurotrophic factor (BDNF) gene not associated with antidepressant-induced mania. Bipolar Disord. 9(5), 521–525 (2007).
   PubMedGoogle Scholar
• de Aguiar Ferreira A, Neves FS, Pimenta GJ et al. The role of genetic variation of BDNF gene in antidepressant-induced mania in bipolar disorder. Psychiatry Res. 180(1), 54–56 (2010).
   PubMedGoogle Scholar
• Feng Y, Vetro A, Kiss E et al. Association of the neurotrophic tyrosine kinase receptor 3 (NTRK3) gene and childhood-onset mood disorders. Am. J. Psychiatry 165(5), 610–616 (2008).
   PubMedGoogle Scholar
• Tadokoro K, Hashimoto R, Tatsumi M et al. Analysis of enhancer activity of a dinucleotide repeat polymorphism in the neurotrophin-3 gene and its association with bipolar disorder. Neuropsychobiology 50(3), 206–210 (2004).
   PubMedGoogle Scholar
• Otsuki K, Uchida S, Watanuki T et al. Altered expression of neurotrophic factors in patients with major depression. J. Psychiatr. Res. 42(14), 1145–1153 (2008).
   PubMed Web of Science ®Google Scholar
• Walz JC, Andreazza AC, Frey BN et al. Serum neurotrophin-3 is increased during manic and depressive episodes in bipolar disorder. Neurosci. Lett. 415(1), 87–89 (2007).
   PubMed Web of Science ®Google Scholar
• Fernandes BS, Gama CS, Walz JC et al. Increased neurotrophin-3 in drug-free subjects with bipolar disorder during manic and depressive episodes. J. Psychiatr. Res. 44(9), 561–565 (2010).
   PubMed Web of Science ®Google Scholar
• Secolin R, Banzato CE, Mella LF et al. Refinement of chromosome 3p22.3 region and identification of a susceptibility gene for bipolar affective disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 162B(2), 163–168 (2013).
   PubMedGoogle Scholar
• Barbosa IG, Huguet RB, Neves FS et al. Impaired nerve growth factor homeostasis in patients with bipolar disorder. World J. Biol. Psychiatry 12(3), 228–232 (2011).
   PubMed Web of Science ®Google Scholar
• Walz JC, Magalhaes PV, Giglio LM et al. Increased serum neurotrophin-4/5 levels in bipolar disorder. J. Psychiatr. Res. 43(7), 721–723 (2009).
   PubMed Web of Science ®Google Scholar
• Petryshen TL, Sabeti PC, Aldinger KA et al. Population genetic study of the brain-derived neurotrophic factor (BDNF) gene. Mol. Psychiatry 15(8), 810–815 (2010).
   PubMed Web of Science ®Google Scholar
• Nugent AC, Diazgranados N, Carlson PJ et al. Neural correlates of rapid antidepressant response to ketamine in bipolar disorder. Bipolar Disord. doi:10.1111/bdi.12118 (2013) ( Epub ahead of print).
   Google Scholar
• Nugent AC, Carlson PJ, Bain EE, et al. Mood stabilizer treatment increases serotonin type 1A receptor binding in bipolar depression. J. Psychopharmacol. 27(10), 894–902 (2013).
   PubMedGoogle Scholar